An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

Completed · Phase 4

Conditions studied: HIV Infection, Hepatitis C

In brief

The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis

Key facts

Study ID

NCT00141284

Run by

Pfizer

People needed

12

Starts

2005-10-01

Expected to finish

2006-12-01

Last updated by the study team

2011-05-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV/ Hepatitic C co infected with documented HCV viremia evidence for cirrhosis and or hepatic fibrosis on liver biopsy, positive fibrosis index, stable health

You may not qualify if…

• Decompensated cirrhosis (Child Pugh B or C)
• Pregnant or lactating women
• History of previous antiretrovirals > 14 days

Where it is running

• Pfizer Investigational Site — Bakersfield, California, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Shreveport, Louisiana, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.